 | Up a level |
Codilupi, Tamara; Szybinski, Jakub; Arunasalam, Stefanie; Jungius, Sarah; Dunbar, Andrew C; Stivala, Simona; Brkic, Sime; Albrecht, Camille; Vokalova, Lenka; Yang, Julie L; Buczak, Katarzyna; Ghosh, Nilabh; Passweg, Jakob R; Rovo, Alicia; Angelillo-Scherrer, Anne; Pankov, Dmitry; Dirnhofer, Stephan; Levine, Ross L; Koche, Richard and Meyer, Sara C (2024). Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clinical cancer research, 30(3), pp. 586-599. American Association for Cancer Research 10.1158/1078-0432.CCR-23-0163
Jungius, Sarah; Adam, Franziska C; Grosheintz, Kerstin; Medinger, Michael; Buser, Andreas; Passweg, Jakob R; Halter, Jörg P; Meyer, Sara C (2023). Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes. Frontiers in oncology, 13(1205387), p. 1205387. Frontiers Research Foundation 10.3389/fonc.2023.1205387
Brkic, Sime; Stivala, Simona; Santopolo, Alice; Szybinski, Jakub; Jungius, Sarah; Passweg, Jakob R; Tsakiris, Dimitrios; Dirnhofer, Stefan; Hutter, Gregor; Leonards, Katharina; Lischer, Heidi E L; Dettmer, Matthias S; Neel, Benjamin G; Levine, Ross L; Meyer, Sara C (2021). Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 35(10), pp. 2875-2884. Springer Nature 10.1038/s41375-021-01391-2
